The Leber congenital amaurosis market is experiencing rapid growth due to advancements in gene therapy technology that can potentially restore vision in patients. Leber congenital amaurosis is a group of inherited retinal disorders caused by mutations in any one of at least 18 genes and is the leading cause of inherited childhood blindness. Gene therapies aim to replace the defective gene responsible for vision loss and help retain or improve visual functions. Some key ongoing clinical trials evaluating gene therapies such as Luxturna, voretigene neparvovec, and RGX-314 are showing promising results in restoring sight in people suffering from Leber congenital amaurosis.

The Global Leber Congenital Amaurosis Market is estimated to be valued at US$ 1.23 Bn in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Leber Congenital Amaurosis Market Demand are Novartis, Biogen, Spark Therapeutics, GenSight Biologics, Roche, AbbVie, Regeneron Pharmaceuticals, Pfizer, Astellas Pharma, Santen Pharmaceutical, Orphan Biovitrum, Apellis Pharmaceuticals, Gilead Sciences, Eyenovia, Avexis, Regenxbio, Horizon Therapeutics, Aerie Pharmaceuticals, Ophthotech Corporation, and Aldeyra Therapeutics. Key players are involved in developing novel gene therapies and obtaining regulatory approvals to commercialize their products.

The growing demand for vision-restoration therapies is a major factor fueling market growth. With no approved treatment options available, the introduction of advanced gene therapies is generating significant optimism among patients and healthcare professionals. Furthermore, ongoing research into understanding genetic causes of Leber congenital amaurosis is also helping the development of new treatment options.

Globally, North America dominated the Leber congenital amaurosis market in 2020 owing to favorable reimbursement policies and the presence of advanced healthcare facilities. However, the Asia Pacific region is expected to exhibit the fastest growth over the forecast period thanks to improving access to healthcare in emerging economies, rising healthcare spending, and a growing patient pool with vision disorders.

Get more insights Leber Congenital Amaurosis market

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)